News

People with cystic fibrosis (CF) tend to report improvements in health-related quality of life associated with treatment with Trikafta. Reports of worse mental health were common, however, and were identified as an area of need. That’s according to data shared by Aricca Van Citters, from The Dartmouth Institute for Health Policy & Clinical Practice,…

Later this month, Laurent Pharmaceuticals will meet with the U.S. Food and Drug Administration (FDA) to discuss next steps for LAU-7b, the company’s experimental inflammation-controlling therapy for cystic fibrosis (CF) that showed promise in a recent Phase 2 study. “There was no precedent in cystic…

Treatment with LAU-7b, an oral form of fenretinide being developed by Laurent Pharmaceuticals, may help prevent lung function decline in adults with cystic fibrosis (CF), particularly those with mild disease, according to results from a Phase 2 clinical trial. Larry Lands, MD, PhD, the company’s chief medical…

The improvements in lung function, respiratory symptoms, and nutritional status with Trikafta are stable after nearly three years in adolescents and adults with cystic fibrosis (CF), according to new data from a long-term extension study. Results were discussed at the 2022 North American Cystic Fibrosis Conference (NACFC) in the presentation, “…

Six months of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) led to significant improvements in lung function and a self-reported easing of respiratory symptoms for children with cystic fibrosis (CF) ages 6 to 11 in an observational study of its real-world use. Felix Ratjen, MD, PhD, division chief of pediatric respiratory…

A single dose of 4D-710, an aerosol gene therapy candidate developed by 4D Molecular Therapeutics (4DMT) for adults with cystic fibrosis (CF), was reported to be safe and restored CFTR protein production in lung tissue samples from three patients enrolled in a Phase 1/2 clinical trial. Interim trial…

Treatment with Trikafta leads to an increase in body weight and cholesterol levels among people with cystic fibrosis (CF), according to a new study into the impacts of the approved CF triple therapy. The study found gains in body mass index — BMI, a measure of body weight…

With continual advances in treatment, more people with cystic fibrosis (CF) are surviving well into adulthood and by 2040, nearly three-quarters of these patients in the U.S. will be adults. That’s according to a study, “Cystic Fibrosis in the United States by 2040: a population landscape…

Women and girls with cystic fibrosis (CF) who are being treated with antibiotics due to a pulmonary exacerbation tend to have better lung function compared with male patients, but report more severe symptoms, new data show. Kristina Montemayor, MD, a professor at Johns Hopkins University, shared the findings at…

CFTR modulators, a highly effective therapy for cystic fibrosis (CF), do not appear to affect fertility outcomes for men using them, data from surveys of these patients indicate. Miscarriages during pregnancy for a woman whose partner is using modulator therapy and congenital anomalies for the child were not higher than expected, researchers reported.